A5001199044- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Genetic factors in colorectal cancer
- Immune cells in cancer
- Esophageal Cancer Research and Treatment
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- interferon and immune responses
- Cancer Mechanisms and Therapy
- Chromatin Remodeling and Cancer
- CAR-T cell therapy research
- Ferroptosis and cancer prognosis
- Cancer Cells and Metastasis
- Gastrointestinal Tumor Research and Treatment
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Cytokine Signaling Pathways and Interactions
- Cancer-related gene regulation
- Cancer-related molecular mechanisms research
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Stress, Anesthesia, and Immune Response
Fukushima Medical University
2018-2025
International Society for Developmental Origins of Health and Disease
2018
Progress (Ireland)
2018
National University of Singapore
2012-2015
National University Health System
2015
University of Yamanashi
2005-2010
Minobusan University
2010
University of Yamanashi Hospital
2004
City Hospital
2001
Abstract Immunotherapy against the interaction between programmed cell death 1/programmed ligand 1 (PD-L1) has emerged as a promising strategy for colorectal cancer with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). The study aimed to identify miRNAs that posttranscriptionally control PD-L1 expression on tumor cells and also regulate immune evasion. A comprehensive miRNA screening using Cancer Genome Atlas (TCGA) dataset (n = 260) combined eight different...
In the present study, we evaluated mechanisms of programmed death ligand 1 (PD‑L1) expression in breast cancer microenvironment, focusing on role interferon‑γ (IFN‑γ), and clinical indications for anti‑programmed cell (PD‑1) /anti‑PD‑L1 immunotherapy. We PD‑L1 4 lines presence 3 types inhibitors, as well IFN‑γ. The phosphorylated signal transducer activator transcription (p‑STAT1), one IFN‑γ signaling pathway molecules, was analyzed using immunohistochemistry (IHC) relation to human...
Immunotherapy targeting PD-1 provides a limited survival benefit in patients with unresectable advanced or recurrent gastric cancer (GC). Beside PD-L1, the expression of inhibitory ligands such as CEACAM-1 and LSECtin on GC cells account for this limitation. Here we assessed their immune suppressive effect patients.Using multiplexed immunohistochemistry staining, evaluated distribution different ligands, including CEACAM-1, LSECtin, MHC class II, 365 patients. We analyzed correlations...
The utilisation of antitumour T cells induced by cancer vaccination with HER-2 peptides or antibodies (Herceptin) against HER-2, as immunotherapy for oesophageal cancer, is a novel and attractive approach. It important to clarify the frequencies expression gene amplification in patients squamous cell carcinoma (SCC) evaluate relationship between status HLA haplotype, since candidates peptide-based are restricted certain haplotype. We determined frequency using HercepTest™...
It has been reported that an increased population of regulatory T cells (T-regs) is one the reasons for impaired anti-tumor immunity. We investigated frequency Foxp3(+) T-regs in tumor-infiltrating lymphocytes (TILs) and peripheral blood (PBLs) patients with esophageal squamous cell carcinoma (ESCC). Furthermore, order to elucidate mechanisms behind accumulation within tumors, we evaluated relationship between CCL17 or CCL22 expression T-regs. CD4(+)CD25(+)Foxp3(+) as a percentage CD4(+)...
X-ray radiotherapy activates tumor antigen-specific T-cell responses, and increases in the serum levels of high mobility group box 1 (HMGB1) induced by irradiation play a pivotal role activating anti-tumor immunity. Here, we examined whether carbon-ion beams, as well X-rays, can induce HMGB1 release from human cancer cell lines. The study five lines: TE2, KYSE70, A549, NCI-H460 WiDr. proportion cells surviving X- or beam was assessed clonogenic assay. D 10 , dose at which 10% survive,...
A small subset of patients with proficient mismatch repair (pMMR)/microsatellite stable (MSS)-colorectal cancer (CRC) benefit from immunotherapy anti-programmed cell death 1 (PD-1)/programmed ligand (PD-L1) blockade. Therefore, the aim current study was to evaluate immune status pMMR/microsatellite instability-low (MSI-L)/MSS-CRC and deficient MMR (dMMR)/MSI-high (MSI-H)-CRC in order identify responders anti-PD-1/PD-L1 inhibitors. The used a dataset downloaded Cancer Genome Atlas (TCGA) as...
Epstein-Barr virus-positive gastric cancer [EBV (+) GC] is a distinct GC subtype with unique genetic and epigenetic aberrations. Here, we examined resected samples publicly available microarray data The Cancer Genome Atlas (TCGA) database to identify the mechanism underlying overexpression of PD-L1 in EBV GC. We found that high levels were caused by focal amplification CD274. By contrast, relatively expression tumor tissue infiltrating immune cells correlated CD8 lymphocyte infiltration...
We previously reported that oesophageal squamous cell carcinoma (SCC) had a relatively high incidence of EGFR and HER-2 overexpression. Thus, anti-HER family targeting may become promising approach to treat SCC. In the present study, we investigated (a) distribution expression in SCC (n=66) detected by immunohistochemistry (b) cetuximab- and/or trastuzumab-mediated biological activity (antiproliferative effect MTT assay, apoptosis-inducing annexin V/propidium iodide antibody-dependent...
TGFβ signaling in the tumor microenvironment (TME) drives immune evasion and is a negative predictor of checkpoint inhibitor (ICI) efficacy colorectal cancer (CRC). TIM-3, an inhibitory receptor implicated anti-tumor responses ICI resistance, has emerged as immunotherapeutic target. This study investigated M2 macrophages TGFβ-activated TME, association with microsatellite instability (MSI) status consensus molecular subtypes (CMSs). Transcriptomic cohorts CRC tissues, organoids xenografts...
Background Tumor-associated antigen (TAA)-specific CD8(+) T cells are essential for nivolumab therapy, and irradiation has been reported to have the potential generate activate TAA-specific cells. However, mechanistic insights of T-cell response during combinatorial immunotherapy using radiotherapy still largely unknown. Methods Twenty patients included in this study were registered CIRCUIT trial (ClinicalTrials.gov, NCT03453164 ). All had multiple distant metastases intolerance or...
TIM-3 was originally identified as a negative regulator of helper T cells and is expressed on dendritic (DCs). Since the inhibition DCs has been suggested to enhance cell-mediated anti-tumor immunity, we examined its expression within tumor microenvironment (TME) in colorectal cancer (CRC) using transcriptomic data from public database (n = 592) immunohistochemical evaluations our cohorts CRC 115). The vitro by flow cytometry, while related molecules, cGAS STING, immature mature assessed...
Adjuvant chemotherapy is considered for patients with stage II colorectal cancer (CRC) characterized by poor prognostic clinicopathological features; however, current stratification algorithms remain inadequate identifying high-risk patients. To develop assays, we conducted a step-wise screening and validation strategy using nine cohorts of based on multiple platforms, including microarray, RNA-sequencing (RNA-seq) immunohistochemistry (IHC) formalin-fixed paraffin-embedded (FFPE) tissues....